Marker Therapeutics Inc (MRKR) Stock Price, Quote & News

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 400 6400

Website: markertherapeutics.com

Address:

2450 Holcombe Blvd, MS: BCM251, Houston, United States

itsMeRich Dec. 12 at 8:13 PM

$MRKR why the wall at $1.46?🤔

1 · Reply

itsMeRich Dec. 11 at 5:08 PM

$MRKR I worry that APVO may be ahead of us with their AML trials - and results. I do own both- but have been in MRKR for many years…. Time will tell if either crosses the finish line or gets acquired.

1 · Reply

contrast82 Dec. 11 at 4:13 PM

$MRKR Marker Therapeutics is a classic acquisition target... Big pharma has one huge problem: Their cancer pipelines are aging and running out of patent protection. Every major oncology company is desperate for:new cell therapies, off-the-shelf T-cell platforms, safer and cheaper alternatives to CAR-T, anything with strong early response rates.MRKR is developing exactly that.Their multi-tumor antigen T-cell therapy (MT-601) is: MUCH safer than CAR-T,significantly cheaper to manufacture,showing strong early responses,backed by CPRIT + NIH (government money). Lets wait and see...

1 · Reply

aperzy20 Dec. 11 at 12:58 PM

$MRKR ANYDAY NOW!

1 · Reply

bullshttt Dec. 11 at 3:08 AM

$MRKR looking for a nice release in the morning.

0 · Reply

TitusPullo1964 Dec. 10 at 6:49 AM

$MRKR

0 · Reply

Awesom69Trade Dec. 10 at 1:51 AM

$MRKR volumes tell me they gonna let it run soon, maybe over $2 tomorrow? If not, then soon. Imo

0 · Reply

WhereAmIGoing Dec. 9 at 9:03 PM

$MRKR nice finish

1 · Reply

ciupycs Dec. 9 at 3:26 PM

$MRKR how big is the 1.45$ wall? Does someone see level 2?

2 · Reply

aperzy20 Dec. 9 at 12:42 PM

$MRKR EXTRMELY

0 · Reply

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 5, 2025, 7:30 AM EST - 5 weeks ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Nov 3, 2025, 9:15 AM EST - 5 weeks ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Oct 6, 2025, 7:30 AM EDT - 2 months ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Aug 28, 2025, 8:00 AM EDT - 3 months ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 12:34 PM EDT - 3 months ago

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Aug 26, 2025, 7:00 AM EDT - 3 months ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Jul 30, 2025, 8:00 AM EDT - 4 months ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Jun 17, 2025, 8:00 AM EDT - 6 months ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

May 20, 2025, 8:00 AM EDT - 7 months ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 19, 2025, 8:00 AM EDT - 7 months ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Apr 1, 2025, 8:00 AM EDT - 9 months ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Mar 31, 2025, 8:45 AM EDT - 9 months ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Feb 25, 2025, 7:00 AM EST - 10 months ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Dec 19, 2024, 8:06 AM EST - 1 year ago

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:05 AM EST - 1 year ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 17, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 10, 2024, 8:30 AM EST - 1 year ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Nov 26, 2024, 11:00 AM EST - 1 year ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 14, 2024, 4:30 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

May 15, 2024, 4:15 PM EDT - 1 year ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Mar 25, 2024, 5:45 PM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 22, 2024, 12:30 PM EDT - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Jan 22, 2024, 7:30 AM EST - 2 years ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 8, 2024, 8:24 AM EST - 2 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Dec 21, 2023, 11:00 AM EST - 2 years ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Nov 9, 2023, 5:00 PM EST - 2 years ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 9:03 AM EDT - 2 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Jul 10, 2023, 7:00 AM EDT - 2 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

May 31, 2023, 6:30 AM EDT - 2 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 8, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 1, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Mar 22, 2023, 8:10 AM EDT - 2 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Dec 13, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Aug 11, 2022, 4:22 PM EDT - 3 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

$Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma$

Aug 4, 2022, 4:37 PM EDT - 3 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

May 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 4, 2022, 10:30 AM EDT - 3 years ago

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

Mar 17, 2022, 5:45 PM EDT - 4 years ago

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

itsMeRich Dec. 12 at 8:13 PM

$MRKR why the wall at $1.46?🤔

1 · Reply

itsMeRich Dec. 11 at 5:08 PM

1 · Reply

contrast82 Dec. 11 at 4:13 PM

1 · Reply

aperzy20 Dec. 11 at 12:58 PM

$MRKR ANYDAY NOW!

1 · Reply

bullshttt Dec. 11 at 3:08 AM

$MRKR looking for a nice release in the morning.

0 · Reply

TitusPullo1964 Dec. 10 at 6:49 AM

$MRKR

0 · Reply

Awesom69Trade Dec. 10 at 1:51 AM

$MRKR volumes tell me they gonna let it run soon, maybe over $2 tomorrow? If not, then soon. Imo

0 · Reply

WhereAmIGoing Dec. 9 at 9:03 PM

$MRKR nice finish

1 · Reply

ciupycs Dec. 9 at 3:26 PM

$MRKR how big is the 1.45$ wall? Does someone see level 2?

2 · Reply

aperzy20 Dec. 9 at 12:42 PM

$MRKR EXTRMELY

0 · Reply

Viperwilder Dec. 9 at 12:35 PM

$MRKR Next stop is 1.59 and after that 1.77, above that we have no resistance

1 · Reply

stonks_2021 Dec. 9 at 4:20 AM

$MRKR easy money

2 · Reply

SimSimBola Dec. 9 at 12:16 AM

$MRKR finally someone sees it. i hinted last week about sudden death. HC Wainwright & Co. is probably gonna handle the next raise thus PT being reaffirmed today. Expect a 100 million volume day shortly. Current holders wiped out. Newbies onboarding. Rinse and repeat. Let me hit that bullish button 😁

0 · Reply

aperzy20 Dec. 8 at 8:32 PM

$MRKR im getting really excited about this one! upgrades to 10$ today LFG

0 · Reply

aperzy20 Dec. 8 at 8:31 PM

$MRKR gonna blast up anytime!

0 · Reply

Awesom69Trade Dec. 8 at 7:42 PM

$MRKR Just give me $5 before xmas. Santa rally is coming to town ho ho ho

0 · Reply

itsMeRich Dec. 8 at 7:21 PM

$MRKR still interesting….. looks to me like slow , methodical accumulation …..by who?

1 · Reply

JarvisFlow Dec. 8 at 2:44 PM

HC Wainwright & Co. updates rating for Marker Therapeutics ( $MRKR ) to Buy, target set at 10.

0 · Reply

contrast82 Dec. 8 at 2:35 PM

$MRKR Investing.com - H.C. Wainwright has reiterated its Buy rating on Marker Therapeutics (NASDAQ:MRKR) stock, maintaining a price target of $10.00, representing over 650% upside from the current price of $1.32. The research firm’s analyst Patrick Trucchio confirmed the rating in a note to investors on Monday, showing continued confidence in the clinical-stage immuno-oncology company. This aligns with the broader analyst consensus, which remains firmly at "Strong Buy" according to InvestingPro data.

0 · Reply

itsMeRich Dec. 8 at 2:34 PM

$MRKR anyone have an update on their presentation at ASH?

2 · Reply

WhereAmIGoing Dec. 8 at 2:52 AM

$MRKR

0 · Reply

Awesom69Trade Dec. 7 at 5:13 PM

$MRKR perfect time for a great PR Monday with updates clinical trial. One solid new, this will pop hard! Imo

0 · Reply

Market Cap	24.51M
Revenue (ttm)	6.59M
Net Income (ttm)	-10.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-162.82%
Debt to Equity Ratio	0.00

Volume	252,900
Avg Vol	273,548
Day's Range	N/A - N/A
Shares Out	16.67M
Stochastic %K	94%
Beta	1.35
Analysts	Strong Sell
Price Target	$8.62